ICER: Madrigal’s Resmetirom Looks More Cost-Effective In NASH Than Intercept’s OCA

 
• By Joseph Haas
  
Economic review
ICER's draft review of leading NASH candidates finds some cost benefit for one • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Scrip